Home Cart Sign in  
Chemical Structure| 1929-29-9 Chemical Structure| 1929-29-9

Structure of 1929-29-9

Chemical Structure| 1929-29-9

3-(4-Methoxyphenyl)propanoic acid

CAS No.: 1929-29-9

4.5 *For Research Use Only !

Cat. No.: A810857 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
5g łÇʶÊÊ Inquiry Inquiry
10g łÇ˶ÊÊ Inquiry Inquiry
25g łÇó¶ÊÊ Inquiry Inquiry
100g łòǶÊÊ Inquiry Inquiry
500g ł§ÊǶÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • 5g

    łÇʶÊÊ

  • 10g

    łÇ˶ÊÊ

  • 25g

    łÇó¶ÊÊ

  • 100g

    łòǶÊÊ

  • 500g

    ł§ÊǶÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Anushree Mondal ; Pronay Roy ; Jaclyn Carrannatto ; Prathamesh M. Datar ; Daniel J. DiRocco ; Katherine Huntera and E. Neil G. Marsh

Abstract: The prenylated-flavin mononucleotide-dependent decarboxylases (also known as UbiD-like enzymes) are the most recently discovered family of decarboxylases. The modified flavin facilitates the decarboxylation of unsaturated carboxylic acids through a novel mechanism involving 1,3-dipolar cyclo-addition chemistry. UbiD-like enzymes have attracted considerable interest for biocatalysis applications due to their ability to catalyse (de)carboxylation reactions on a broad range of aromatic substrates at otherwise unreactive carbon centres. There are now ∼35[thin space (1/6-em)]000 protein sequences annotated as hypothetical UbiD-like enzymes. Sequence similarity network analyses of the UbiD protein family suggests that there are likely dozens of distinct decarboxylase enzymes represented within this family. Furthermore, many of the enzymes so far characterized can decarboxylate a broad range of substrates. Here we describe a strategy to identify potential substrates of UbiD-like enzymes based on detecting enzyme-catalysed solvent deuterium exchange into potential substrates. Using ferulic acid decarboxylase (FDC) as a model system, we tested a diverse range of aromatic and heterocyclic molecules for their ability to undergo enzyme-catalysed H/D exchange in deuterated buffer. We found that FDC catalyses H/D exchange, albeit at generally very low levels, into a wide range of small, aromatic molecules that have little resemblance to its physiological substrate. In contrast, the sub-set of aromatic carboxylic acids that are substrates for FDC-catalysed decarboxylation is much smaller. We discuss the implications of these findings for screening uncharacterized UbiD-like enzymes for novel (de)carboxylase activity.

Alternative Products

Product Details of [ 1929-29-9 ]

CAS No. :1929-29-9
Formula : C10H12O3
M.W : 180.20
SMILES Code : O=C(O)CCC1=CC=C(OC)C=C1
MDL No. :MFCD00002777
InChI Key :FIUFLISGGHNPSM-UHFFFAOYSA-N
Pubchem ID :95750

Safety of [ 1929-29-9 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 1929-29-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 13
Num. arom. heavy atoms 6
Fraction Csp3 0.3
Num. rotatable bonds 4
Num. H-bond acceptors 3.0
Num. H-bond donors 1.0
Molar Refractivity 49.29
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

46.53 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.69
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.9
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.71
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.67
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.91
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.78

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.23
Solubility 1.06 mg/ml ; 0.00586 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.5
Solubility 0.57 mg/ml ; 0.00316 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.71
Solubility 0.354 mg/ml ; 0.00196 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.05 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.56

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.12

Application In Synthesis of [ 1929-29-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1929-29-9 ]

[ 1929-29-9 ] Synthesis Path-Downstream   1~4

  • 1
  • [ 1929-29-9 ]
  • [ 15893-42-2 ]
YieldReaction ConditionsOperation in experiment
100% With phosgene; In water monomer; at 20℃; for 4h; General procedure: Cinnamoyl chlorides - Derivatives of cinnamic acid were stirred with oxalyl chloride (5 ml g-1) for up to 4 h. The stirring time differed depending on the dissolution rate of the starting cinnamic acid derivative. For derivatives with 4-NO2 or 4-N(CH3)2 substituents, a drop of dry N,N-DMF was added to catalyze the reaction. The excess reagent was evaporated under reduced pressure. The hydroxy groups in the hydroxycinnamic acid derivatives were acetylated prior to reaction with oxalyl chloride by stirring the derivative (0.0244 mol) in acetic anhydride (5 ml g-1) and pyridine (0.5 ml) at room temperature (rt, ~20 C) overnight. Cold water (~50 ml) was added to the mixture and stirred for further 5-10 min with cooling in an ice-water bath, and the resulting precipitate of acetoxycinnamic acid was obtained by vacuum filtration, washed with cold water and dried.Methyl N-cinnamoylanthranilates - The cinnamoyl chloride (0.014 mol) was added to a solution of excess methyl anthranilate (0.017 mol) in dry pyridine (10 ml g-1), and the mixture was stirred for an hour at rt. Cold water (250 ml) was added to the reaction mixture and the resulting precipitate was filtered and washed with cold water until free of pyridine, and was recrystallized from hot ethanol. In contrast, methyl N-hydrocinnamoylanthranilate derivatives, with a low melting point, were extracted in diethyl ether (2 × 70 ml), washed with cold water (2 × 50 ml) and the solvent evaporated under reduced pressure.N-Cinnamoylanthranilic acids - The methyl N-cinnamoylanthranilate (0.010 mol) was stirred in a mixture of THF (100 ml) and methanol (20 ml), and LiOH.H2O (0.050 mol) [LiOH dissolved in water 0.2 g per 10 ml] was added to the reaction mixture and stirred at rt overnight. The excess reagent and solvents were evaporated under reduced pressure. The crude product was dissolved in water (~350 ml) and acidified slowly to pH 4 using dilute HCl (1 M) with stirring. The precipitate was obtained by vacuumfiltration, washed with water and dried, and was recrystallized from hot aqueous ethanol (water-ethanol, 1:4). In the case of N-hydroxycinnamoylanthranilate derivatives, water was added to the resulting solution to aid crystallization.α-Methylcinnamic acid - To a mixture of benzaldehyde (5 ml, 0.0492 mol) and propionic anhydride61 (10 ml, 0.0780 mol), anhydrous sodium acetate (2.5 g) was added and heated under reflux for 4 h. Once the mixture has cooled down to rt, cold water (50 ml) was added and alkalized with saturated aqueous sodium carbonate (85 ml). The resulting solid suspension was heated up to dissolve completely, and the unreacted benzaldehyde was extracted in DCM (2 × 25 ml) and the aqueous layer was acidified with concentrated HCl (12 M) with cooling. The pale yellowish white crystals (yield 2.098 g, 26 %) of α-methylcinnamic acid was obtained by vacuum filtration, washed with little cold water (~10 ml) and dried.
With thionyl chloride; In toluene; a) Preparation of 3-(4-methoxyphenyl)propionyl Chloride To a suspension of 3-(4-methoxyphenyl)propionic acid (10 g) in 150 ml of toluene are added 8 ml of thionyl chloride and the mixture is heated to 65 C. for 4 hours. The solvent is evaporated off under reduced pressure and the residue is redissolved in toluene and concentrated to dryness. Such steo is repeated twice. 11 g of the product are obtained as a yellow oil.
With thionyl chloride; In dichloromethane; for 3h;Reflux; General procedure: A solution of 3-(4-fluorophenyl)propionic acid (300 mg, 1.8 mmol) in dry CH2Cl2 (20 mL) was treated with thionyl chloride (2.2 mL, 30.2 mmol). The reaction mixture was refluxed for 3 h and the solvent was then removed until dryness. A translucent oil, corresponding to 3-(4-fluorophenyl)propanoyl chloride, was obtained and used directly in the next reaction under the same conditions described in the general procedure.
With oxalyl dichloride; N,N-dimethyl-formamide; In dichloromethane; for 2h; Step 1 Oxalyl chloride (5 eq) was added to a solution of 4-methoxyphenyl)propionic acid (1 eq) in CH2CI2 (0.1 M), and then a catalytic amount of DMF was added to the reaction mixture to initiate the reaction and bubbling occurred. The reaction was complete in 2 hours, and the solution was dried with N2 for one hour to give the acid chloride, which was used immediately in the next step.
With thionyl chloride; In N,N-dimethyl-formamide; toluene; at 75℃; for 3h; A solution of p-methoxyphenylpropionic acid (12a, 2.99 mmol), SOCl2 (2 mL) and DMF (2 drops) was added to toluene (20 mL) and stirred at 75C for 3 h. The reaction was terminated and the solution was concentrated to dryness under reduced pressure to give p-methoxyphenylpropionyl chloride (13a). (6,2.61 mmol), pyridine (1 mL) in CH2Cl2 (10 mL) was added dropwise with stirring Oxyphenylpropionyl chloride (13a). After completion of the dropwise addition, the reaction was refluxed for 2 h. The reaction was completed, cooled to room temperature, poured into dilute hydrochloric acid, stirred. Extracted with dichloromethane, and washed with saturated brine. The solvent was concentrated to dryness under reduced pressure to give crude product. Column chromatography (petroleum ether / ethyl acetate: 15/1, V / V) gave a white solid in 66.8%
With phosphorus(V) chloride; In dichloromethane;Reflux; General procedure: To a solution of phosphorus pentachloride (0.126 g, 0.610 mmol) in dichloromethane (11 mL), phenoxyacetic acid (0.092 g, 0.610 mmol) was added with stirring and the mixture refluxed for 30-40 minutes. After cooling, 4-methyl-1,2,5-oxadiazol-3-amine (0.060 g, 0.610 mmol) was added and the solution refluxed for 2-2.5 hours. The solvent was removed under reduced pressure and the residue quenched with water (50 mL). The solid was collected by vacuum filtration and washed with saturated sodium bicarbonate solution followed by water to afford compound 19 (0.103 g, 73%)
With oxalyl dichloride; N,N-dimethyl-formamide; In dichloromethane; at 20℃; for 5h; General procedure: An oven-dried flask was charged with aliphatic carboxylic acid (1.00 equiv) and CH2Cl2 (0.50 M). Three drops of N,N-dimethylformamide (DMF) and oxalyl chloride (1.20 equiv, 1.00 M) in DCM were added dropwise. The reaction mixture was stirred vigorously at room temperature for 5 h and then evaporated DCM and redundant oxalyl chloride under the vacuum. The crude acid chloride was used for the next reaction without any further purification
With oxalyl dichloride; N,N-dimethyl-formamide; at 20℃; for 1h;Inert atmosphere; General procedure: Oxalyl chloride (2equiv) was added at room temperature into asolutioncarboxylic acids(1equiv) in anhydrous dichloromethane. Added one drop ofN,N-dimethylformamide and reacted under nitrogen atmosphere for 1h. The solvent was removed under vacuum, yielding a crude product that were stored in a nitrogen atmosphere for subsequent use without further purified.

References: [1]European Journal of Medicinal Chemistry,2005,vol. 40,p. 764 - 771.
[2]Journal of the American Chemical Society,2015,vol. 137,p. 7656 - 7659.
[3]European Journal of Medicinal Chemistry,2019,vol. 170,p. 141 - 156.
[4]Organic Letters,2020,vol. 22,p. 2902 - 2907.
[5]Journal of the Chemical Society,1909,vol. 95,p. 1722.
[6]Journal of Medicinal Chemistry,1981,vol. 24,p. 451 - 454.
[7]Journal of Medicinal Chemistry,1986,vol. 29,p. 2465 - 2472.
[8]Phytochemistry,1981,vol. 20,p. 1097 - 1104.
[9]Journal of the Chemical Society. Perkin transactions I,1982,p. 2407 - 2412.
[10]Journal of Heterocyclic Chemistry,2003,vol. 40,p. 519 - 522.
[11]Synlett,2004,p. 477 - 480.
[12]Pharmazie,2004,vol. 59,p. 744 - 752.
[13]Journal of Medicinal Chemistry,2006,vol. 49,p. 1494 - 1498.
[14]Journal of Organic Chemistry,2000,vol. 65,p. 4179 - 4184.
[15]Journal of Organic Chemistry,2001,vol. 66,p. 7166 - 7177.
[16]Patent: US6110924,2000,A .
[17]Organic Letters,2008,vol. 10,p. 2601 - 2604.
[18]Patent: US6335332,2002,B1 .Location in patent: Page column 11.
[19]Organic and Biomolecular Chemistry,2009,vol. 7,p. 3561 - 3571.
[20]Journal of Medicinal Chemistry,2009,vol. 52,p. 3366 - 3376.
[21]Organic Letters,2010,vol. 12,p. 3990 - 3993.
[22]Molecular Crystals and Liquid Crystals,2011,vol. 545,p. 149 - 155.
[23]Journal of the American Chemical Society,2013,vol. 135,p. 7442 - 7445.
[24]Bioorganic and Medicinal Chemistry,2013,vol. 21,p. 3221 - 3230.
[25]Synlett,2012,vol. 23,p. 2389 - 2392.
[26]Organic Letters,2014,vol. 16,p. 1268 - 1268.
[27]Patent: WO2015/35051,2015,A1 .Location in patent: Page/Page column 232.
[28]Advanced Synthesis and Catalysis,2016,vol. 358,p. 887 - 893.
[29]Angewandte Chemie - International Edition,2016,vol. 55,p. 6988 - 6991.
    Angew. Chem.,2016,vol. 128,p. 7102 - 7105,4.
[30]Journal of the American Chemical Society,2017,vol. 139,p. 2200 - 2203.
[31]Patent: CN106146450,2016,A .Location in patent: Paragraph 0204; 0205; 0206.
[32]Angewandte Chemie - International Edition,2017,vol. 56,p. 12307 - 12311.
    Angew. Chem.,2017,vol. 129,p. 12475 - 12479,5.
[33]Bioorganic and Medicinal Chemistry,2017,vol. 25,p. 6267 - 6272.
[34]Journal of Medicinal Chemistry,2018,vol. 61,p. 5199 - 5221.
[35]Organic Letters,2019,vol. 21,p. 3625 - 3630.
[36]Tetrahedron,2019,vol. 75,p. 4186 - 4191.
[37]Bioorganic and Medicinal Chemistry Letters,2019,vol. 29,p. 2327 - 2331.
[38]Journal of the American Chemical Society,2019,vol. 141,p. 16362 - 16373.
[39]Angewandte Chemie - International Edition,2021,vol. 60,p. 171 - 175.
    Angew. Chem.,2021,vol. 133,p. 173 - 177,5.
[40]Journal of Medicinal Chemistry,2021,vol. 64,p. 1844 - 1855.
[41]Organic Letters,2021,vol. 23,p. 3310 - 3314.
[42]Biomolecules,2022,vol. 12.
[43]Bioorganic and Medicinal Chemistry Letters,2022,vol. 64.
  • 2
  • [ 109-72-8 ]
  • [ 1929-29-9 ]
  • [ 3282-30-2 ]
  • [ 70-07-5 ]
  • [ 104-21-2 ]
YieldReaction ConditionsOperation in experiment
With triethylamine; In tetrahydrofuran; hexane; L-phenylalanine; B. Preparation of 13, 15 2-p-Methoxybenzyl acetic acid 12 (3.92 g, 0.02 mol) was dissolved in 100 mlof ether and cooled to -78 C. under a nitrogen atmosphere. Triethylamine was added (2.86 ml, 0.0205 mol) followed by pivaloyl chloride (2.52 ml, 0.0205 mol). The mixture was warmed to 0 C. over 30 min. and then stirred at 0 C. for 2 hr. to give mixed anhydride 13. The solution was then cooled to -78 C. (SOLUTION A). In a separate flask the (S) phenylalanine derived oxazolidinone 14 (3.45 g,0.0195 mol) was dissolved in 30 ml of tetrahydrofuran and cooled to -78 C. under a nitrogen atmosphere. n-Butyllithium (14.3 ml of a 1.36M solution in hexane) was added via cannula, and then was stirred for 15 min at -78 C. (SOLUTION B). Solution B was then added, via cannula, to solution A at -78 C. Theresulting mixture was stirred 15 min at -78 C., warmed to 0C. over 30 min, and then stirred for 1 hr at 0 C. Sixty ml of waterwas then added and the mixture was extracted with 3*50 ml of methylene chloride. The combined organic extracts were washed with 50 ml of saturated sodium bicarbonate solution and 50 ml of saturated sodium chloride solution and were dried over sodium sulfate. Concentration in vacuo and flash chromatography with silica gel (elution with 3:1, hexanes:ethyl acetate) gave the desired p-methoxybenzyl acetate derived oxazolidinone imide 15 (5.51 g).
With triethylamine; In tetrahydrofuran; hexane; L-phenylalanine; water; B. Preparation of 17. 19 2-p-Methoxybenzyl acetic acid 16 (3.92 g, 0.02 mol) was dissolved in 100 ml of ether and cooled to -78 C. under a nitrogen atmosphere. Triethylamine was added (2.86 ml, 0.0205 mol) followed by Pivaloyl chloride (2.52 ml, 0.0205 mol). The mixture was warmed to 0 C. over 30 min. and then stirred at 0 C. for 2 hr. to give mixed anhydride 17. The solution was then cooled to -78 C. (SOLUTION A). In a separate flask the (S) phenylalanine derived oxazolidinone 18 (3.45 g, 0.0195 mol) was dissolved in 30 ml of tetrahydrofuran and cooled to -78 C. under a nitrogen atmosphere. n-Butyllithium (14.3 ml of a 1.36 M solution in hexane) was added via cannula, and then was stirred for 15 min. at -78 C. (SOLUTION B). Solution B was then added, via cannula, to solution A at -78 C. The resulting mixture was stirred 15 min. at -78 C., warmed to 0 C. over 30 min., and then stirred for 1 hour at 0 C. Sixty ml of water was then added and the mixture was extracted with 3*50 ml of methylene chloride. The combined organic extracts were washed with 50 ml of saturated sodium bicarbonate solution and 50 ml of saturated sodium chloride solution and were dried over sodium sulfate. Concentration in vacuo and flash chromatography with silica gel (elution with 3:1, hexanes:ethyl acetate) gave the desired p-methoxybenzyl acetate derived oxazolidinone imide 19 (5.51 g).
  • 4
  • [ 1929-29-9 ]
  • [ 15893-42-2 ]
  • [ 40608-04-6 ]
YieldReaction ConditionsOperation in experiment
General procedure: To a flamed-dried flask with magnetic stir bar, was added aliphatic acid (1.0 equiv), dried DCM (1.0 M) and triethylamine (1.05 equiv) successively. The solution was stirred for 30 minutes at 0 0C. Then acyl chloride (1.05 equiv) was added dropwise to the mixture and stirred overnight at rt. The solvent was evaporated by vacuum to afford the crude mixture. And the mixture was dissolved in n-hexane. Then the residue was filtered through a small plug of celite and concentrated to afford the anhydrides. This product was used to next catalytic reaction without any further purification.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 1929-29-9 ]

Aryls

Chemical Structure| 4521-28-2

A132991 [4521-28-2]

4-(4-Methoxyphenyl)butyric acid

Similarity: 1.00

Chemical Structure| 10516-71-9

A215933 [10516-71-9]

3-(3-Methoxyphenyl)propionic acid

Similarity: 1.00

Chemical Structure| 717-94-2

A150921 [717-94-2]

3-(3,5-Dimethoxyphenyl)propionic acid

Similarity: 0.95

Chemical Structure| 20637-08-5

A165433 [20637-08-5]

Methyl 4-(4-methoxyphenyl)butanoate

Similarity: 0.93

Chemical Structure| 2107-70-2

A268016 [2107-70-2]

3-(3,4-Dimethoxyphenyl)propionic acid

Similarity: 0.93

Ethers

Chemical Structure| 4521-28-2

A132991 [4521-28-2]

4-(4-Methoxyphenyl)butyric acid

Similarity: 1.00

Chemical Structure| 10516-71-9

A215933 [10516-71-9]

3-(3-Methoxyphenyl)propionic acid

Similarity: 1.00

Chemical Structure| 717-94-2

A150921 [717-94-2]

3-(3,5-Dimethoxyphenyl)propionic acid

Similarity: 0.95

Chemical Structure| 20637-08-5

A165433 [20637-08-5]

Methyl 4-(4-methoxyphenyl)butanoate

Similarity: 0.93

Chemical Structure| 2107-70-2

A268016 [2107-70-2]

3-(3,4-Dimethoxyphenyl)propionic acid

Similarity: 0.93

Carboxylic Acids

Chemical Structure| 4521-28-2

A132991 [4521-28-2]

4-(4-Methoxyphenyl)butyric acid

Similarity: 1.00

Chemical Structure| 10516-71-9

A215933 [10516-71-9]

3-(3-Methoxyphenyl)propionic acid

Similarity: 1.00

Chemical Structure| 717-94-2

A150921 [717-94-2]

3-(3,5-Dimethoxyphenyl)propionic acid

Similarity: 0.95

Chemical Structure| 2107-70-2

A268016 [2107-70-2]

3-(3,4-Dimethoxyphenyl)propionic acid

Similarity: 0.93

Chemical Structure| 6342-77-4

A461673 [6342-77-4]

3-(2-Methoxyphenyl)propanoic acid

Similarity: 0.93